# A Study of Imvotamab in Severe Systemic Lupus Erythematosus

> **NCT06041568** · PHASE1 · TERMINATED · sponsor: **IGM Biosciences, Inc.** · enrollment: 17 (actual)

## Conditions studied

- Systemic Lupus Erythematosus
- Lupus Erythematosus

## Interventions

- **DRUG:** Imvotamab

## Key facts

- **NCT ID:** NCT06041568
- **Lead sponsor:** IGM Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-08-15
- **Primary completion:** 2025-01-27
- **Final completion:** 2025-01-27
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** Company Decision.
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06041568

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06041568, "A Study of Imvotamab in Severe Systemic Lupus Erythematosus". Retrieved via AI Analytics 2026-07-09 from https://api.ai-analytics.org/clinical/NCT06041568. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*